Chargement en cours...

Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib

Despite the huge success of tyrosine kinase inhibitors as anticancer agents, severe side effects are a major problem. In order to overcome this drawback, the first hypoxia-activatable 2-nitroimidazole-based prodrugs of the clinically approved ALK and c-MET inhibitor crizotinib were developed. The 2-...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Bioorg Chem
Auteurs principaux: Bielec, Bjoern, Schueffl, Hemma, Terenzi, Alessio, Berger, Walter, Heffeter, Petra, Keppler, Bernhard K., Kowol, Christian R.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611434/
https://ncbi.nlm.nih.gov/pubmed/32229347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bioorg.2020.103778
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!